GSK, Alcon And Otsuka Obtain Japanese Approval Recommendations
This article was originally published in PharmAsia News
Japan's First Committee on New Drugs at Japan's Ministry of Health, Labor and Welfare granted approval recommendations July 30 to GlaxoSmithKline's anti-allergic agent Xyzal (levocetirizine), Alcon Japan's Nevanac (nepafenac) for pain and swelling after cataract surgery, and Otsuka Pharmaceutical's Samsca (tolvaptan) for hypervolemic hyponatremia
You may also be interested in...
The UK medicines regulator has a “unique opportunity” to evaluate the systems it operates and to “do things differently", according to its long-term interim head, June Raine.
No device-related warning letters were released by the US FDA the week of 22 September.
Created in 2016 by consolidating five European companies, CNS specialist Neuraxpharm is changing hands, with funds advised by global investor Permira paying an undisclosed sum to take control of a business boasting annual revenues of around €460m ($541m) and more than 115 CNS molecules at its disposal.